Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC filing details

Document Details

Form
Filing Date
Feb 17, 2021
Document Date
Dec 31, 2020
Form Description
Annual report which provides a comprehensive overview of the company for the past year
Filing Group
Annual Filings
Company
Blueprint Medicines Corp.
Issuer
Blueprint Medicines Corp